Navigation Links
FDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
Date:4/6/2012

rson reader training program for physicians using Amyvid. Errors may occur in the estimation of plaque density during image interpretation.

About Amyvid
Amyvid is a radioactive diagnostic agent tagged with a radioisotope called fluorine-18. Once Amyvid is injected into a vein, it travels through the bloodstream and into the brain, binding to amyloid plaques. Amyvid produces a positron signal, which is detected by a PET scanner and used to create a brain image. A radiologist, who should have successfully completed Amyvid reader training, then interprets the image to evaluate for the presence or absence of significant amyloid plaques (i.e., moderate to frequent levels of neuritic plaques) in the brain. This information is reported back to the referring physician, who then determines the next steps in the evaluation and management of the patient.

Indication and Important Safety Information About Amyvid

Indication
Amyvid is a radioactive diagnostic agent for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of Alzheimer's Disease at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's Disease. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with Alzheimer's Disease, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.

Limitations of Use:
A positive Amyvid scan does not establish a diagnosis
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB)
2. FDA Approves Additional Manufacturer of Methoxsalen
3. FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen
4. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
5. FDA Approves Gleevec For Expanded Use in Patients With Rare Gastrointestinal Cancer
6. FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
7. ASAM Approves Prescription Drug Policy
8. FDA Approves Picato® (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
9. FDA Approves Shared REMS (Risk Evaluation and Mitigation Strategy) Program for all TIRF (Transmucosal Immediate Release Fentanyl) Pain Treatments
10. FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
11. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 STAAR Surgical Company (NASDAQ: ... of implantable lenses and delivery systems for the eye ... 4, 2014 of $20.0 million, a 10% increase over ... On a constant currency basis, revenues grew 11% during ... quarter of 2013.  The effect of foreign currency exchange ...
(Date:7/31/2014)... -- ResMed Inc. (NYSE: RMD ) today announced results ... June 30, 2014.  Revenue for the quarter was $415.2 million, ... 1 percent decrease on a constant currency basis). Net income ... the quarter ended June 30, 2013. Diluted earnings per share ... compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... plays a central role in regulating appetite and whole-body ... the brain,s control of food intake and body weight, ... has been unclear. A new study in ... PPARγ activity in a type of neuron known as ... to high-fat diet. Sabrina Diano and colleagues at ...
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... filed in the wake of the 2012 Rejuvenate ... to move forward in New Jersey’s Bergen County ... documents filed in the proceeding, the Court has ... of Confidentiality governing any and all hard copy ...
(Date:8/1/2014)... first-of-its-kind study, researchers at University Hospitals Rainbow Babies & ... be at greater risk for death on a commercial ... flights worldwide between January 2010 and June 2013 and ... the age of 2. , The study was ... event of an in-flight pediatric fatality onboard commercial airline ...
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
Breaking Medicine News(10 mins):Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5
... injuries in people, doctors monitor blood level increases of ... the severity of the injury. Creatinine is filtered by ... early damage to vital kidney function. For pets suffering ... found that even tiny increases of creatinine in blood ...
... Dec. 19 (HealthDay News) -- Blood pressure changes in middle ... stroke, a new study suggests. U.S. researchers analyzed data ... for an average of 14 years. People who kept ... 55 had the lowest lifetime risk (22 percent to 41 ...
... MONDAY, Dec. 19 (HealthDay News) -- ,A new study finds ... one of the most aggressive forms of skin cancer. The ... Cutaneous melanoma is the fifth most commonly diagnosed cancer in ... U.S. women. Incidence of the cancer is increasing, and death ...
... Acupuncture significantly reduces levels of a protein in ... Medical Center (GUMC) have found. They say their animal ... many people receive from this ancient Chinese therapy., Published ... the researchers say that if their findings are ...
... molecules derived naturally in the body from a major ... acids [EETs]) are currently in clinical trials for the ... of researchers led by Dipak Panigrahy and Mark ... at the Institute for Systems Biology, Seattle; and Darryl ...
... called EETs currently under scrutiny as possible treatment targets ... the growth and spread of cancer, according to researchers at ... findings also raise the possibility that drugs that block EETs ... This study, led by Dipak Panigrahy, MD, of DF/CHCC and ...
Cached Medicine News:Health News:MU researchers find pet kidney injuries are similar to human kidney injuries 2Health News:Blood Pressure Control in Middle Age Can Lower Lifetime Heart Risk 2Health News:Previous Cancer May Up Melanoma Risk 2Health News:Acupuncture reduces protein linked to stress in first of its kind animal study 2Health News:Targeting EETs to treat cardiovascular disease may prove a double-edged sword 2Health News:Targeting EETs to treat cardiovascular disease may prove a double-edged sword 3
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTT/1P chairs are recommended for the ... room, static control, health care and ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTT/1P chairs are recommended for the ... room, static control, health care and ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: